166 related articles for article (PubMed ID: 33277750)
21. LAT1 acts as a crucial transporter of amino acids in human thymic carcinoma cells.
Hayashi K; Jutabha P; Maeda S; Supak Y; Ouchi M; Endou H; Fujita T; Chida M; Anzai N
J Pharmacol Sci; 2016 Nov; 132(3):201-204. PubMed ID: 27567475
[TBL] [Abstract][Full Text] [Related]
22. Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics.
Jin SE; Jin HE; Hong SS
Expert Opin Ther Targets; 2015; 19(10):1319-37. PubMed ID: 25968633
[TBL] [Abstract][Full Text] [Related]
23. Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors.
Fan X; Ross DD; Arakawa H; Ganapathy V; Tamai I; Nakanishi T
Biochem Pharmacol; 2010 Sep; 80(6):811-8. PubMed ID: 20510678
[TBL] [Abstract][Full Text] [Related]
24. The Role of Large Neutral Amino Acid Transporter (LAT1) in Cancer.
Lu X
Curr Cancer Drug Targets; 2019; 19(11):863-876. PubMed ID: 31376820
[TBL] [Abstract][Full Text] [Related]
25. [Drug Discovery Targeting an Amino Acid Transporter for Diagnosis and Therapy].
Wiriyasermkul P; Moriyama S; Kongpracha P; Nagamori S
Yakugaku Zasshi; 2021; 141(4):501-510. PubMed ID: 33790117
[TBL] [Abstract][Full Text] [Related]
26. Specific transport of 3-fluoro-l-α-methyl-tyrosine by LAT1 explains its specificity to malignant tumors in imaging.
Wei L; Tominaga H; Ohgaki R; Wiriyasermkul P; Hagiwara K; Okuda S; Kaira K; Oriuchi N; Nagamori S; Kanai Y
Cancer Sci; 2016 Mar; 107(3):347-52. PubMed ID: 26749017
[TBL] [Abstract][Full Text] [Related]
27. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor.
Okanishi H; Ohgaki R; Okuda S; Endou H; Kanai Y
Cancer Sci; 2021 Feb; 112(2):871-883. PubMed ID: 33264461
[TBL] [Abstract][Full Text] [Related]
28. Tyrosine-Chlorambucil Conjugates Facilitate Cellular Uptake through L-Type Amino Acid Transporter 1 (LAT1) in Human Breast Cancer Cell Line MCF-7.
Pocasap P; Weerapreeyakul N; Timonen J; Järvinen J; Leppänen J; Kärkkäinen J; Rautio J
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32244913
[TBL] [Abstract][Full Text] [Related]
29. Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells: LAT1 is a promising molecular target for human cancer therapy.
Ohkawa M; Ohno Y; Masuko K; Takeuchi A; Suda K; Kubo A; Kawahara R; Okazaki S; Tanaka T; Saya H; Seki M; Enomoto T; Yagi H; Hashimoto Y; Masuko T
Biochem Biophys Res Commun; 2011 Mar; 406(4):649-55. PubMed ID: 21371427
[TBL] [Abstract][Full Text] [Related]
30. Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell Line.
Takahashi Y; Nishimura T; Higuchi K; Noguchi S; Tega Y; Kurosawa T; Deguchi Y; Tomi M
Pharm Res; 2018 Oct; 35(12):246. PubMed ID: 30374619
[TBL] [Abstract][Full Text] [Related]
31. System L amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET).
Habermeier A; Graf J; Sandhöfer BF; Boissel JP; Roesch F; Closs EI
Amino Acids; 2015 Feb; 47(2):335-44. PubMed ID: 25385314
[TBL] [Abstract][Full Text] [Related]
32. Stimulation of 125I-3-iodo-alpha-methyl-L-tyrosine uptake in Chinese hamster ovary (CHO-K1) cells by tyrosine esters.
Shikano N; Ogura M; Sagara J; Nakajima S; Kobayashi M; Baba T; Yamaguchi N; Iwamura Y; Kubota N; Kawai K
Nucl Med Biol; 2010 Feb; 37(2):189-96. PubMed ID: 20152718
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.
Imai H; Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Nagamori S; Promchan K; Nakajima T; Yamamoto N; Mori M; Kanai Y
Anticancer Res; 2010 Dec; 30(12):4819-28. PubMed ID: 21187458
[TBL] [Abstract][Full Text] [Related]
34. The L-Type Amino Acid Transporter LAT1-An Emerging Target in Cancer.
Häfliger P; Charles RP
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31100853
[TBL] [Abstract][Full Text] [Related]
35. A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
Huttunen KM; Gynther M; Huttunen J; Puris E; Spicer JA; Denny WA
J Med Chem; 2016 Jun; 59(12):5740-51. PubMed ID: 27253989
[TBL] [Abstract][Full Text] [Related]
36. L-Type amino acid transporter 1 as a target for drug delivery.
Puris E; Gynther M; Auriola S; Huttunen KM
Pharm Res; 2020 May; 37(5):88. PubMed ID: 32377929
[TBL] [Abstract][Full Text] [Related]
37. Properties of L-type amino acid transporter 1 in epidermal ovarian cancer.
Kaji M; Kabir-Salmani M; Anzai N; Jin CJ; Akimoto Y; Horita A; Sakamoto A; Kanai Y; Sakurai H; Iwashita M
Int J Gynecol Cancer; 2010 Apr; 20(3):329-36. PubMed ID: 20375792
[TBL] [Abstract][Full Text] [Related]
38. Large amino acid transporter 1 mediated glutamate modified docetaxel-loaded liposomes for glioma targeting.
Li L; Di X; Zhang S; Kan Q; Liu H; Lu T; Wang Y; Fu Q; Sun J; He Z
Colloids Surf B Biointerfaces; 2016 May; 141():260-267. PubMed ID: 26859117
[TBL] [Abstract][Full Text] [Related]
39. Differential expression and functional characterization of system L amino acid transporters in human normal osteoblast cells and osteogenic sarcoma cells.
Kim SG; Kim HH; Kim HK; Kim CH; Chun HS; Kanai Y; Endou H; Kim DK
Anticancer Res; 2006; 26(3A):1989-96. PubMed ID: 16827134
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma.
Ohshima Y; Kaira K; Yamaguchi A; Oriuchi N; Tominaga H; Nagamori S; Kanai Y; Yokobori T; Miyazaki T; Asao T; Tsushima Y; Kuwano H; Ishioka NS
Cancer Sci; 2016 Oct; 107(10):1499-1505. PubMed ID: 27465934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
